ArticleNews reportPHN-05162026-11-01 17:40 CT

PharmaTher develops 3D printed colon-targeted peptide tablets

Source · VoxelMatters

TLDR

VoxelMatters reports that PharmaTher is developing 3D-printed, colon-targeted KPV and BPC-157 tablets under an interim U.S. compounding pathway. A cited laboratory study delivered up to 75% of budesonide to a simulated colon using the delivery technology, but evidence for the proposed peptide treatment remains limited.

01—Key points

01The tablets use Craft Health’s CORR3CT technology, with a pH-responsive shell designed to resist stomach acid.
02The article describes a conditional compounding pathway and states that neither peptide was FDA-approved.
03Evidence for the lead target, left-sided ulcerative colitis, was limited to KPV studies in mice and early rectal BPC-157 use in humans.

Why it matters Editorial

The development explores targeted oral peptide delivery, but the cited laboratory results concern budesonide rather than demonstrated clinical benefits of these peptide tablets.

Read the original at VoxelMatters↗

Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.